$24.21
-1.15 (-4.53%)
Open$25.36
Previous Close$25.36
Day High$25.75
Day Low$23.31
52W High$38.33
52W Low$2.45
Volume—
Avg Volume537.7K
Market Cap1.73B
P/E Ratio—
EPS$-12.01
SectorBiotechnology
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.65M | 7.80M | 6.88M |
| Net Income | -2,097,514 | -1,645,262 | -1,540,052 |
| Profit Margin | -27.4% | -21.1% | -22.4% |
| EBITDA | -2,154,773 | -2,236,853 | -1,912,817 |
| Free Cash Flow | -1,120,093 | -988,846 | -1,121,747 |
| Rev Growth | +8.4% | +22.8% | +24.7% |
| Debt/Equity | 0.85 | 0.67 | 0.79 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |